Results 221 to 230 of about 36,256 (261)

Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab. [PDF]

Transl Lung Cancer Res
Tokito T, Azuma K, Murotani K, Matsuo N, Matama G, Murata D, Sasada T, Hoshino T.   +7 more
europepmc   +1 more source

Supplementary Figure S2 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC

Pablo Llerena, Hani Samarah, Kathryn Nunes, Zhao Lin, Kelly Bridgham, Sruti Tekumalla, Amiti Jain, Larry A. Harshyne, Sanket K. Shukla, Ioannis Vathiotis, Madalina Tuluc, Stacey Gargano, John R. Eisenbrey, Scott W. Keith, David M. Cognetti, Voichita Bar‐Ad, Adam Luginbuhl, Rita Axelrod, Rajanikanth Vadigepalli, Hushan Yang, Diana Whitaker‐Menezes, Megan Roche, Mỹ G. Mahoney, Athanassios Argiris, Charalambos Solomides, Jennifer M. Johnson, Mouadh Barbirou, Amanda Miller, Andrew P. South, Ramkrishna Mitra, Alban J. Linnenbach, Ubaldo Martinez‐Outschoorn, Joseph Curry   +32 more
openalex   +1 more source

Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study. [PDF]

Hosp Pharm
Castellana E, Budau PM, Chiappetta MR.
europepmc   +1 more source

Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study. [PDF]

Front Oncol
Sitthideatphaiboon P, Reungwetwattana T, Jaruhathai S, Supavavej A, Limpawittayakul P, Maneenil K, Korphaisarn K, Suksombooncharoen T, Thongthieang L, Sathitruangsak C, Chayangsu C, Ratanabunjerdkul H, Prasongsook N, Sriuranpong V.   +13 more
europepmc   +1 more source

Efficacy of combined immunotherapy and chemotherapy in recurrent non-small cell lung cancer during durvalumab maintenance therapy: A case report. [PDF]

Oncol Lett
Maze Y, Mitsumura T, Nakahama H, Kato T, Takahashi Y, Nei Y, Hanada S, Miyamoto A, Uruga H, Fujii T, Tamaoka M.   +10 more
europepmc   +1 more source

Successful stent removal after chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer with airway stenosis: A report of three cases

Yuki Takigawa, Ken Sato, Daisuke Minami, Kenichiro Kudo, Shoichiro Matsumoto, Miho Fujiwara, Takeru Ichikawa, Tomoyoshi Inoue, Suzuka Matsuoka, Hiromi Watanabe, Akiko Sato, Hiroyasu Shoda, Nobuhisa Ishikawa, Keiichi Fujiwara, Takuo Shibayama   +14 more
openalex   +1 more source

Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network. [PDF]

Ther Adv Med Oncol
Lin HC, Tseng KY, Shih YH.
europepmc   +1 more source

Durvalumab plus cisplatin and gemcitabine in advanced biliary tract cancer: can we do it better? [PDF]

Hepatobiliary Surg Nutr
Rimini M, Casadei-Gardini A.
europepmc   +1 more source

Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial

Séverine Guiu, Judith Balmañà, Pablo Lemercier, Philippe Follana, Anthony Gonçalvès, Frédéric Bigot, Jean‐Sébastien Frenel, Étienne Brain, Audrey Mailliez, Camille Chakiba, Elsa Curtit, Olfa Derbel, Florence Dalenc, Fanny Derquin, François P. Duhoux, Jean-Luc Canon, Isabel Pimentel, Louise-Marie Chevalier, Adrien Buisson, Clara Guyonneau, Jérôme Lemonnier, Suzette Delaloge, Thomas Bachelot   +22 more
openalex   +1 more source

Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial. [PDF]

Cancer Sci
Zenke Y, Shiraishi Y, Goto Y, Azuma K, Okishio K, Ogino H, Horio Y, Oizumi S, Hayama M, Nii M, Harada M, Mann H, Olivo YS, Jiang H, Senan S.   +14 more
europepmc   +1 more source